Treatment of Advanced Metastatic Melanoma
The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the o...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Mattioli1885
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/fc9ee1c4f4f647f099d8873a21b3f64b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:fc9ee1c4f4f647f099d8873a21b3f64b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:fc9ee1c4f4f647f099d8873a21b3f64b2021-11-17T08:27:38ZTreatment of Advanced Metastatic Melanoma10.5826/dpc.11S1a164S2160-9381https://doaj.org/article/fc9ee1c4f4f647f099d8873a21b3f64b2021-07-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/1881https://doaj.org/toc/2160-9381 The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS). The long-term results of trials with follow-up data of patients treated with targeted or immunotherapies reported median OS rates around 24 months, with 5-year survival rates around 35-40%. As to the drugs currently available and reimbursed by the Italian National Health System, 3 combinations of anti-BRAF/anti-MEK inhibitors are available (dabrafenib/trametinib, vemurafenib/cobimetinib and the most recently introduced encorafenib/binimetinib). As for checkpoint inhibitors, first line immunotherapy is represented by anti-PD1 blockers (nivolumab and pembrolizumab), whilst the anti-CTLA-4 ipilimumab can be used as second line immunotherapy. The decision-making factors that define the best treatment approach in stage IV patients with metastatic melanoma include the mutation pattern, performance status, high/low tumor load, brain metastases, progression pattern (low/fast), and availability of clinical trials. This review will analyze the current therapeutic tools adopted for the treatment of metastatic melanoma patients. It will then focus on the latest results obtained by novel treatments (checkpoint inhibitors and targeted therapies) which can be used in the clinical daily practice. Pietro QuaglinoPaolo FavaLuca TonellaMarco RubattoSimone RiberoMaria Teresa FerroMattioli1885articleMetastatic melanoma treatmentanti-PD1target therapymetastatic melanoma survivalresponse rateDermatologyRL1-803ENDermatology Practical & Conceptual, Vol 11, Iss S1 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Metastatic melanoma treatment anti-PD1 target therapy metastatic melanoma survival response rate Dermatology RL1-803 |
| spellingShingle |
Metastatic melanoma treatment anti-PD1 target therapy metastatic melanoma survival response rate Dermatology RL1-803 Pietro Quaglino Paolo Fava Luca Tonella Marco Rubatto Simone Ribero Maria Teresa Ferro Treatment of Advanced Metastatic Melanoma |
| description |
The introduction in clinical practice of new drug compounds both targeted therapies anti-BRAF and checkpoint inhibitors have largely improved our potential to manage advanced metastatic melanoma patients. This has led to a significant improvement in terms of response rates and particularly in the overall survival (OS). The long-term results of trials with follow-up data of patients treated with targeted or immunotherapies reported median OS rates around 24 months, with 5-year survival rates around 35-40%. As to the drugs currently available and reimbursed by the Italian National Health System, 3 combinations of anti-BRAF/anti-MEK inhibitors are available (dabrafenib/trametinib, vemurafenib/cobimetinib and the most recently introduced encorafenib/binimetinib). As for checkpoint inhibitors, first line immunotherapy is represented by anti-PD1 blockers (nivolumab and pembrolizumab), whilst the anti-CTLA-4 ipilimumab can be used as second line immunotherapy. The decision-making factors that define the best treatment approach in stage IV patients with metastatic melanoma include the mutation pattern, performance status, high/low tumor load, brain metastases, progression pattern (low/fast), and availability of clinical trials. This review will analyze the current therapeutic tools adopted for the treatment of metastatic melanoma patients. It will then focus on the latest results obtained by novel treatments (checkpoint inhibitors and targeted therapies) which can be used in the clinical daily practice.
|
| format |
article |
| author |
Pietro Quaglino Paolo Fava Luca Tonella Marco Rubatto Simone Ribero Maria Teresa Ferro |
| author_facet |
Pietro Quaglino Paolo Fava Luca Tonella Marco Rubatto Simone Ribero Maria Teresa Ferro |
| author_sort |
Pietro Quaglino |
| title |
Treatment of Advanced Metastatic Melanoma |
| title_short |
Treatment of Advanced Metastatic Melanoma |
| title_full |
Treatment of Advanced Metastatic Melanoma |
| title_fullStr |
Treatment of Advanced Metastatic Melanoma |
| title_full_unstemmed |
Treatment of Advanced Metastatic Melanoma |
| title_sort |
treatment of advanced metastatic melanoma |
| publisher |
Mattioli1885 |
| publishDate |
2021 |
| url |
https://doaj.org/article/fc9ee1c4f4f647f099d8873a21b3f64b |
| work_keys_str_mv |
AT pietroquaglino treatmentofadvancedmetastaticmelanoma AT paolofava treatmentofadvancedmetastaticmelanoma AT lucatonella treatmentofadvancedmetastaticmelanoma AT marcorubatto treatmentofadvancedmetastaticmelanoma AT simoneribero treatmentofadvancedmetastaticmelanoma AT mariateresaferro treatmentofadvancedmetastaticmelanoma |
| _version_ |
1718425840474128384 |